key: cord-1031062-3tea19f3 authors: Bhowmik, Deep; Nandi, Rajat; Jagadeesan, Rahul; Kumar, Niranjan; Prakash, Amresh; Kumar, Diwakar title: Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches date: 2020-07-05 journal: Infect Genet Evol DOI: 10.1016/j.meegid.2020.104451 sha: e8f9b70a4c59e2a0a8e1c4ebac2b3fcad5540c5c doc_id: 1031062 cord_uid: 3tea19f3 WHO has declared the outbreak of COVID-19 as a public health emergency of international concern. The ever-growing new cases have called for an urgent emergency for specific anti-COVID-19 drugs. Three structural proteins (Membrane, Envelope and Nucleocapsid protein) play an essential role in the assembly and formation of the infectious virion particles. Thus, the present study was designed to identify potential drug candidates from the unique collection of 548 anti-viral compounds (natural and synthetic anti-viral), which target SARS-CoV-2 structural proteins. High-end molecular docking analysis was performed to characterize the binding affinity of the selected drugs-the ligand, with the SARS-CoV-2 structural proteins, while high-level Simulation studies analyzed the stability of drug-protein interactions. The present study identified rutin, a bioflavonoid and the antibiotic, doxycycline, as the most potent inhibitor of SARS-CoV-2 envelope protein. Caffeic acid and ferulic acid were found to inhibit SARS-CoV-2 membrane protein while the anti-viral agent's simeprevir and grazoprevir showed a high binding affinity for nucleocapsid protein. All these compounds not only showed excellent pharmacokinetic properties, absorption, metabolism, minimal toxicity and bioavailability but were also remain stabilized at the active site of proteins during the MD simulation. Thus, the identified lead compounds may act as potential molecules for the development of effective drugs against SARS-CoV-2 by inhibiting the envelope formation, virion assembly and viral pathogenesis. Apart from their primary roles, they are also involved in other aspects of the replication cycle. The M protein is the crucial player in CoV assembly. When expressed alone, it accumulates in the Golgi complex in the homo-multimeric complex and is insufficient for virion formation [12] [13] [14] . However, in combination with the E protein, virus-like particles (VLPs) are assembled, indicating the combination of M and E proteins as the minimal requirements for the envelope formation or the production and release of VLPs [15, 16] . The N protein is the only structural protein that directly links up with the replicasetranscriptase complexes (RTCs) [17, 18] . This protein binds to the CoV RNA genome, which is essential for incorporating the viruses' genetic material into CoV particles [19, 20] . Its function involves entering the host cell, binding to the viral RNA genome and forming the ribonucleoprotein core [21, 22] . Though, for SARS-CoV, the interaction of N with M was found to be independent of viral RNA [23, 24] . The localization of N to the ER-Golgi region has proposed a function in assembly and budding [25, 26] . Studies suggest that binding of N protein to M protein stabilizes the nucleocapsid as well as the internal core of the virions, promoting the completion of viral assembly [27, 28] . Apart from their primary function, N protein is also involved in virus replication, transcription, translation and host pathological response to viral infection [21, 29] . The E protein contains a single hydrophobic domain and is a minor component of the virion envelope [30] . Though expressed abundantly, only a small amount is incorporated into the viral envelope; the rest of the E protein is localized to ER, Golgi and ERGIC [31] . Studies have shown that the recombinant CoVs lacking E protein exhibit significantly reduced viral titer or incompetent virus propagation [32] . Based on literature three roles have been proposed for E protein, i.e., assembly process based on its interaction with M protein, resulting in driving the production of VLPs; release of infectious viruses that require the hydrophobic domain (HD) of the E protein and lastly, form ion channels, which is mainly associated with pathogenesis [33] [34] [35] [36] [37] . Due to the high infection rate of the COVID-19 patient, it calls for an urgent need for effective therapies or existing treatment strategies [38, 39] . Due to the extensive membrane perturbation caused by the CoVs, it is not surprising that the membrane- Energy minimization of E, M and N protein structure was carried out by YASARA Energy Minimization Server [44] to obtain an energy-minimized and highly stable protein structure validated by PROCHECK [45] . Structural quality and reliability of E and M protein structures were validated through ERRAT, Verify3D and ProSa [46-48]. Binding site residues were anticipated through literature study and different pocketbinding site-recognition web servers such as the CASTp server, and the HotSpot Both natural anti-viral compounds and synthetic anti-viral drugs were selected as ligands against E, M and N protein. More than 200 natural compounds, including alkaloids, flavonoids, quinone, tannins, terpenes, steroids, thiophenes, polyacetylenes, lactones, butenolide and lectins were selected as ligands [52, 53] . In contrast, an antiviral compound library with a unique collection of 348 anti-viral compounds used for investigating novel anti-viral drugs was selected from Selleckchem.com (https://www.selleckchem.com/). All the natural compounds were obtained from the PubChem database in smi format (SMILES format) and stored in a single file, whereas the anti-viral compounds from Selleckchem.com were downloaded and J o u r n a l P r e -p r o o f saved in sdf (MDL MOL format) file. The SMILES and MDL MOL format was converted to pdbqt (AutoDock PDBQT format) file by OPENBABEL, to molecular docking. In molecular docking, validation of docking protocol is necessary to ensure that ligands bind within the binding pocket in the correct conformation, which is done by validating the size and center of the grid box's coordinates across the binding pocket The pharmacological profiling of the selected ligands was carried out by analyzing Lipinski's violation of 5, which was evaluated through Molsoft L.L.C.: Drug-Likeness and molecular property prediction for drug-likeness All-atoms MD simulations were performed on the atomic coordinates of the best- hydrogen and long-range electrostatic forces treated with PME (Particle mesh Ewald). The system was equilibrated in two steps, NVT and NPT at 300 K for a period of 500 ps. During the simulation, Berendsen thermostat [62] and Parrinello-Rahman pressure [63] were used to maintain pressure and temperature. LINC algorithm was used to constrain the bonds and angles [64] . The van der Waals interactions are taken care of by LJ potential with a cutoff of 0.10 nm. Using the NPT ensemble, production runs were performed for the period of 100, with time integration. The energy, velocity and trajectory were updated at the time interval of 10 ps. All production runs were done on CUDA enabled Tesla GPU machine (DELL T640 with V100 GPU) and OS Centos 7 [65, 66] and the Gromacs utilities were used for the analyses of obtained MD trajectories. I-TASSER evaluates the full-length model using parameters such as C-score, which is the confidence score, TM-score (Template Modeling Score) and RMSD Table S1 ). The C-score for both the models was adequate, signifying the proper homology modeling for both the proteins and acceptable TM-score and RMSD values ( showed that all residues were in favored, additionally allowed and generously allowed regions (Fig. S4A) . Thus, we obtained good quality models for E, M and N protein. Errat, Verify3D and ProSa [46-48] further evaluated the energy minimized structure with the calculation of Errat value of 96.92% and 95.93% for E and M protein structure, respectively ( Fig. S2B & S3B) . The Z-score and energy plots by ProSa indicated an overall good quality model for both E and M protein. The active site of protein was generated using a literature study and cross verified The docking study carried out with the natural as well as synthetic anti-viral agents as ligands against the E, M and N protein of SARS-CoV-2 provided the structural insight of molecular interactions. We find that most of the natural ligands interact with all three target proteins more or less efficiently, but the ligands with the lowest dock energy against a particular protein were assigned as a potential target and their interaction studies in detail. Natural bioflavonoid rutin and anti-bacterial as well antiviral agent doxycycline [67, 68] showed the best result with E protein, having a docking score of -9.3 kcal/mol and -9.1 kcal/mol, respectively ( Table 2 ). The two hydrocinnamic acids, i.e., caffeic acid and ferulic acid is belonging to phenylpropanoids, obtained as best docked against the M protein of SARS-CoV-2 with docking score of -8.4 kcal/mol and -8.3 kcal/mol, respectively ( Table 2) . Simeprevir and grazoprevir showed an excellent docking result against N protein with docking energy of -8.7 kcal/mol and -8.5 kcal/mol, respectively, in PyRx ( Table 2) . The best docking pattern of compounds are shown in site residues Thr91 and Arg93 (Fig. 5E ), whereas, grazoprevir shows interaction with two tyrosine residues Tyr109 and Tyr111 through H-bonding (Fig. 5F ). to be the best inhibitor against E protein, it was also observed that rutin interact and form H-bond with active site residues of both the M and N protein with a docking score of -7.7 kcal/mol and -7.9 kcal/mol respectively in PyRx ( Table 2) . While caffeic acid and ferulic acid were found to form H-bond with active site residues of both E and N protein. The docking score of caffeic acid against E and N protein was found to be -6.1 kcal/mol and -7.4 kcal/mol respectively ( Table 2) , whereas, the docking scores of ferulic acid was -6.0 kcal/mol and -7.2 kcal/mol against E and N protein respectively ( Table 2 The pharmacological studies first assessed the selected ligands against E, M and N protein for a good oral administration based on the Lipinski rule of five [69] , which was evaluated through Molsoft L.L.C.: Drug-Likeness and molecular property prediction. Lipinski's "rule of five" is a heuristic approach for predicting drug-likeness stating that molecules had Molecular weight (M.W. <500 Dalton), high lipophilicity expressed as LogP (LogP <5), hydrogen bond donors (HBD <5) and hydrogen bond acceptors (HBA <10) have good absorption or permeation across the cell membrane. Doxycycline, caffeic acid and ferulic acid did not show any Lipinski violation, while rutin was found to violate Lipinski rule as observed from Table 3 in terms of its high molecular weight, more than 5 HBD and more than 10 HBA. Apart from possessing a high molecular weight, both simeprevir and grazoprevir did not violate any other Lipinski rule. Drug molecules of higher molecular weight are not readily transported and have poor absorption compared to molecules with low molecular weight [70] . The absorption percentage (AB%) was calculated using the formula [71, 72] J o u r n a l P r e -p r o o f Journal Pre-proof AB% = 109 -(0.345 x TPSA). The AB% (>50%) of a drug is a good indication of its excellent bioavailability, distribution and circulation by oral route a [73] [74] [75] . Only rutin was found to possess an AB% of 35 (<50%), which was due to its high polar surface area (PSA) of 213.63 Ǻ 2 while PSA ≤ 140 Ǻ 2 was proposed optimal [76] . All the remaining inhibitors apart from rutin possessed AB% greater than 50% (Table 3) , an excellent evaluation of these selected ligands to have proper bioavailability for an oral route [73] . Only caffeic acid and ferulic acid showed a negative drug-likeness score as assessed by Molsoft L.L.C. software ( Table 3) . Ligands with negative drug score are generally not considered as a potential drug candidate [77] . for its remedial use against various diseases [82] [83] [84] . The bioactivity of the selected ligands checked through molinspiration and calculated the activity against GPCR ligand, ion channel modulator, a kinase inhibitor, nuclear receptor ligand, protease inhibitor and enzyme inhibitor [75] . The bioactivity values were interpreted as: active (bioactivity score > 0), moderately active (bioactivity score: -5.0-0.0) and inactive (bioactivity score < -5.0) [85] . Rutin and doxycycline were evaluated as active enzyme inhibitors with values 0.12 and 0.59, respectively. Caffeic acid and ferulic acid were moderately active against enzyme inhibition as well as nuclear receptor ligand. Simeprevir and grazoprevir were evaluated as active protease inhibitors by molinspiration, which supports the fact that these two compounds are an HCV NS3/4A protease inhibitor [86] [87] [88] [89] [90] . The bioactivity prediction by molinspiration is tabulated in Table 4 . [91] , the ADMET properties of the selected ligands were thus compared with it. All the selected ligands showed optimal solubility with values higher than -4 (>-4) [75] and immensely satisfying results with some of the values even better than the control drugs, as shown in Table 5 . The selected inhibitors against E, M and N protein of SARS CoV-2 have excellent human intestinal absorption (HIA), good Caco2 permeability values and were expected to be highly absorbed in the intestine upon oral administration ( Table 5 ) [92] . Simeprevir showed the highest HIA at 0.99, which is indicative of its better absorption rate. All the selected inhibitors also possessed better values for the bloodbrain barrier (BBB) and Caco2 permeability ( Table 5 ). In terms of metabolism, rutin, doxycycline, caffeic acid and ferulic acid were found to be non-inhibitor of cytochrome P450 (CYP 450), indicating its proper metabolism by CYP450 ( Table 5) . A non-inhibitor of CYP450 means that the drug molecule will not hamper in the biotransformation of drug metabolism by CYP 450 enzyme [93] . All the selected inhibitors were non-AMES toxic and non-carcinogens, while hydroxychloroquine was evaluated as AMES toxic in admetSAR ( Table 5) . A compound with lower LD50 doses is more lethal than the compound having higher LD50 [93] . admetSAR analysis revealed all the selected inhibitors with optimal LD50 doses indicating they are nonlethal ( Table 5 ). RMSF complies that the average fluctuation of residues belonging to stable secondary conformations remains below 0.25 nm, which is also observed consistent with binding pocket residues and Thr35 for E and Lys50 for M, which was found in H-bond interactions in docking results ( Figure 6B) . Whereas RMSF fluctuations for N protein residues against simeprevir and grazoprevir also showed fewer fluctuations (<1.0 nm) in the binding site residues Thr91 and Arg93 for simeprevir and residues Tyr109 and Tyr111 for grazoprevir (Fig. 7B) . The binding site residues for all the three proteins in protein-ligand complexes from the RMSF study are favorable in molecular J o u r n a l P r e -p r o o f interactions; thus, a stable conformational dynamic of protein-ligand interaction is observed during simulation, which was in excellent agreement with docking analyses. Furthermore, we also examine the solvent-accessible surface area (SASA) of proteinligand complexes. SASA ensures the contribution of hydrophobic interactions of the nonpolar amino to the conformation stability of proteins in the solvent environment [103] [104] [105] [106] . Results show quite a stable SASA plot of E protein complex with rutin and doxycycline, which is stabilized throughout simulation with 42 nm 2 ( Figure 6D) . Similarly, the stable structure of M protein with caffeic acid and ferulic acid is maintained with SASA value 135 nm 2 ( Figure 6D) . Whereas, the SASA plots of N protein docked complex with simeprevir and grazoprevir show that an average SASA value of 167 and 167.48 is maintained during the simulation ( Figure 7C) . Thus, SASA results indicate no significant changes in the proteins solvent accessible, which again provided the stable conformational dynamics of ligand, bound structures. To determine the conformational stability of protein-ligands, we also computed the time evolution plot of R g (Figure 6E and 7D) . Results show that the R g trajectory of rutin optimizes at ~40 ns and remains stable during 40-100 ns, signifying that ligand is well accommodated at the active site of the E protein ( Figure 6E) . The R g trajectory of doxycycline reaches equilibrium ~20 ns and a stable equilibrium is seen during 20-100 ns, which indicates that ligand is well fitted in the binding pocket. We do not find any significant change in the R g trajectory of Caffeic acid ( Figure 6E ). R g achieves equilibrium quickly in a few nanoseconds, and an unperturbed structure is sustained until simulation finished at 100 ns with the average change in R g value 1.83±0.01( Figure 6E) . We find an initial rise in R g of Ferulic acids; however, complex structure smoothly settles ~20 ns, and a compact structure is propagated for the remaining period of simulation ( Figure 6E) . The R g plots of simeprevir and grazoprevir with N protein reveals that the structural compactness of complex structures remains stable, with the average change in R g value 15. 3±0.02 and 15. 25±0.02 throughout the simulation period, thus, favoring the spatial interaction at the active site of N protein ( Figure 7D ). Figure (Fig. 8C) . Thus, MD simulation of the protein-ligand complexes for all the three proteins against their selected ligands leads to the establishment of our complexes to be basically and structurally stable and reliable. J o u r n a l P r e -p r o o f In this study we evaluated the envelope (E), membrane (M) and nucleocapsid (N) protein as a potential drug target and molecular docking was carried out to find a potential inhibitor against these three proteins, which are essential for coronavirus assembly, envelop formation, pathogenesis and replication. We found that rutin, a Table 2) . Pharmacological studies of the selected inhibitors for the Lipinski rule of 5 indicated rutin, simeprevir and grazoprevir with a high molecular weight [70] . Although simeprevir and grazoprevir did not violate any other Lipinski parameters, as shown in Table 3 . However, earlier studies described rutin as a potential inhibitor against rotavirus and enterovirus with IC50 values of 98 µM and 109.63 µM, respectively [107] . Also, rutin has powerful antioxidants and different pharmacological properties [108, 109] . Doxycycline, caffeic acid and ferulic acid did not violate the Lipinski rule and possessed excellent pharmacological properties for a better oral drug (Table 3) . Generally, compounds with a negative drug score are not considered as a potential drug [90] , but the anti-viral activity of caffeic acid and ferulic acid against different viruses as discussed above, cannot be neglected [78] [79] [80] [81] , and both can be considered hepatic damage [86] [87] [88] . Grazoprevir was well tolerable with a dose of once-daily or in combination with Elbasvir against Hepatitis C replication and possessed good pharmacokinetic profiles [90] . The bioactivity of the selected inhibitors against SARS CoV-2 structural E, M and N protein was carried out, which was also supportive of our selected inhibitors. The ADMET studies for the selected inhibitors were checked and evaluated through the admetSAR. All the compounds were compared with the control/ reference drugs taken in the study. Lastly, results from MD simulation supported our choice of inhibitors evaluated against their particular protein target. The protein-ligand complexes for E, M and N were stable throughout the simulation period as interpreted by RMSD, RMSF, SASA, Rg, PE and H-bond graphs (Fig. 6, 7 & 8) . Thus molecular, docking, pharmacokinetic profiling and MD simulation outcome supports our choice of inhibitors as potential inhibitors against E, M and N protein of SARS CoV-2 and may inhibit envelope formation, virion assembly and viral pathogenesis. The study evaluated the bioflavonoid rutin and the anti-bacterial and anti-viral agent J o u r n a l P r e -p r o o f Going global -Travel and the 2019 novel coronavirus. Travel medicine and infectious disease A pneumonia outbreak associated with a new coronavirus of probable bat origin The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 Coronaviruses post-SARS: update on replication and pathogenesis Coronaviruses: an overview of their replication and pathogenesis Coronavirus entry and release in polarized epithelial cells: a review A Novel Coronavirus from Patients with Pneumonia in China Global Epidemiology of Bat Coronaviruses The spike glycoprotein of the new coronavirus 2019-nCoV contains a furinlike cleavage site absent in CoV of the same clade The proteome of the infectious bronchitis virus Beau-R virion A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding A structural analysis of M protein in coronavirus assembly and morphology The missing link in coronavirus assembly. Retention of the avian coronavirus infectious bronchitis virus envelope protein in the pre-Golgi compartments and physical interaction between the envelope and membrane proteins The production of recombinant infectious DI-particles of a murine coronavirus in the absence of helper virus Nucleocapsid-independent assembly of coronavirus-like particles by co-expression of viral envelope protein genes An interaction between the nucleocapsid protein and a component of the replicasetranscriptase complex is crucial for the infectivity of coronavirus genomic RNA The coronavirus nucleocapsid protein is dynamically associated with the replication-transcription complexes Structures of the N-and C-terminal domains of MHV-A59 nucleocapsid protein corroborate a conserved RNA-protein binding mechanism in coronavirus A key role for the carboxyterminal tail of the murine coronavirus nucleocapsid protein in coordination of genome packaging The coronavirus nucleocapsid is a multifunctional protein Biochemical characterization of SARS-CoV-2 nucleocapsid protein Characterization of protein-protein interactions between the nucleocapsid protein and membrane protein of the SARS coronavirus Severe acute respiratory syndrome coronavirus membrane protein interacts with nucleocapsid protein mostly through their carboxyl termini by electrostatic attraction Replication of coronavirus MHV-A59 in sac-cells: determination of the first site of budding of progeny virions Coronavirus M proteins accumulate in the Golgi complex beyond the site of virion budding The membrane M protein carboxy terminus binds to transmissible gastroenteritis coronavirus core and contributes to core stability Characterization of the coronavirus M protein and nucleocapsid interaction in infected cells Nucleocapsid protein-dependent assembly of the RNA packaging signal of Middle East respiratory syndrome coronavirus Coronavirus envelope (E) protein remains at the site of assembly Subcellular location and topology of severe acute respiratory syndrome coronavirus envelope protein Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway The missing term in effective pair potentials Crystal Structure and Pair Potentials: A Molecular-Dynamics Study LINCS: A linear constraint solver for molecular simulations Delineating the conformational dynamics of intermediate structures on the unfolding pathway of β-lactoglobulin in aqueous urea and dimethyl sulfoxide Elucidation of stable intermediates in urea-induced unfolding pathway of human carbonic anhydrase IX Inhibitory effect of doxycycline against dengue virus replication in vitro Antiviral activity of doxycycline against vesicular stomatitis virus in vitro Lead-and drug-like compounds: the rule-of-five revolution Computer-aided design of selective Cytochrome P450 inhibitors and docking studies of alkyl resorcinol derivatives Rate-limited steps of human oral absorption and QSAR studies Synthesis, molecular properties, toxicity and biological evaluation of some new substituted imidazolidine derivatives in search of potent anti-inflammatory agents A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases Impact of Pregnancy on Maternal Pharmacokinetics of Medications Drug-Likeness and Pharmacokinetics of a bis-Phenolic Ligand: Evaluations by Computational Methods Molecular properties that influence the oral bioavailability of drug candidates Molecular properties prediction, docking studies and antimicrobial screening of ornidazole and its derivatives Polymeric phenylpropenoids are the active components in the pine cone extract that inhibit the replication of type-1 human immunodeficiency virus in vitro Antihepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro Antiviral activity of metal chelates of caffeic acid and similar compounds towards herpes simplex, VSV-Ebola pseudotyped and vaccinia viruses Inhibition Mechanisms of Hepatitis C Virus Infection by Caffeic Acid and Tannic Acid Inhibitory effect of ferulic acid and isoferulic acid on the production of macrophage inflammatory protein-2 in response to respiratory syncytial virus infection in RAW264.7 cells Potential New H1N1 Neuraminidase Inhibitors from Ferulic Acid and Vanillin: Molecular Modelling Ferulic Acid: therapeutic potential through its antioxidant property In Vitro Absorption Studies and Their Relevance to Absorption from the GI Tract Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study Simeprevir: a macrocyclic HCV protease inhibitor Once-daily simeprevir (TMC435) with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1-infected patients in Japan: the DRAGON study MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antiviral Activity, Safety, and Tolerability of Multiple Ascending Doses of Elbasvir or Grazoprevir in Participants Infected With Hepatitis C Virus Genotype-1 or -3 Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-Secretase Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of Mycobacterium Tuberculosis In silico study of naphtha [1, 2-d] thiazol-2-amine with adenosine A 2A receptor and its role in antagonism of haloperidol-induced motor impairments in mice Docking of HIV-1 Vpr to the nuclear envelope is mediated by the interaction with the nucleoporin hCG1 The HDOCK server for integrated protein-protein docking Discovery of novel Methylsulfonyl phenyl derivatives as potent human Cyclooxygenase-2 inhibitors with effective anticonvulsant action: Design, synthesis, in-silico, in-vitro and in-vivo evaluation Identification of potential inhibitors for Klebsiella pneumoniae carbapenemase-3: a molecular docking and dynamics study Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation Evaluation of potential drugs against leishmaniasis targeting catalytic subunit of Leishmaniadonovani nuclear DNA primase using ligand based virtual screening, docking and molecular dynamics approaches Characterization of the protein unfolding processes induced by urea and temperature TFE-induced local unfolding and fibrillation of SOD1: bridging the experiment and simulation studies Vitro Inhibitory Effect of Some Flavonoids on Rotavirus Infectivity Fisetin and rutin as 3C protease inhibitors of enterovirus A71 A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells A Novel Bat Coronavirus Closely Related to SARS-CoV-2 Contains Natural Insertions at the S1/S2 Cleavage Site of the Spike Protein Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites M'Caffeic"acid M'Caffeic"acid The authors declare that no conflict of interest exists. DK, DB, RJ, RN, NK and AP carried out the experiment. DB, RN, AP and DK wrote the manuscript. DK, DB, RJ, RN and AP contributed to the analysis of the results. DK supervised the project and conceived the original idea.